Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Icosavax, Inc. (ICVX) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2022 | -50,051,000 | 20.52 M | 238.68 M | 223.91 M | |
| 2021 | -279,082,000 | 9.41 M | 287.63 M | 286.55 M | |
| 2020 | -8,167,000 | 42.87 M | 16.17 M | 16.16 M | |
| 2019 | -23,079,000 | 31.53 M | 23.29 M | 23.29 M |